Table 1.
Baseline characteristics and laboratory results of patients hospitalized with COVID-19.
| Number of patients tested | ||
|---|---|---|
| Baseline characteristics | 38 | .. |
| Age, years | .. | .. |
| Median (IQR) | .. | 68 (55–74) |
| Sex, n (%) | .. | .. |
| Female | .. | 21 (55.3) |
| Male | .. | 17 (44.7) |
| Coexisting conditions, n (%) | 38 | .. |
| Any | .. | 29 (76.3) |
| Hypertension | .. | 19 (50.0) |
| Diabetes | .. | 6 (15.8) |
| Chronic pulmonary disease | .. | 6 (15.8) |
| Coronary heart disease | .. | 7 (18.4) |
| Chronic neurological disorder | .. | 5 (13.2) |
| Chronic kidney disease | .. | 2 (5.3) |
| Vital signs, median (IQR) | 38 | .. |
| Heart rate, bpm | .. | 82 (78.0–89.0) |
| Systolic pressure, mmHg | .. | 123 (117.8–128.5) |
| Diastolic pressure, mmHg | .. | 70 (65.8–80.0) |
| SpO2, % | .. | 98 (95.8–99.0) |
| Laboratory results, n (%) | .. | .. |
| CRP abnormal | 36 | 26 (72.2) |
| D-dimer abnormal | 26 | 22 (84.6) |
| Albumin abnormal | 37 | 20 (54.1) |
| Lymphocyte count abnormal | 38 | 19 (50.0) |
| AST abnormal | 37 | 13 (35.1) |
| TnI abnormal | 30 | 9 (30.0) |
| BNP abnormal | 21 | 8 (38.1) |
| Myoglobin abnormal | 30 | 8 (26.7) |
| CK-MB abnormal | 30 | 0 |
| Chest CT findings, n (%) | 38 | .. |
| Bilateral distribution of patchy | .. | 38 (100) |
| Shadows or ground-glass opacity | ||
| Complications, n (%) | 38 | .. |
| Cardiac injury | .. | 16 (42.1) |
| Liver injury | .. | 13 (35.1) |
| Kidney injury | .. | 3 (8.8) |
| Use of ARBs, n (%) | 38 | 3 (8.8) |
Data are median (IQR) and n (%).
ARB, angiotensin II type-I receptor blocker; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; CK-MB, creatine kinase-MB; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; IQR, interquartile range; SpO2, pulse oxygen saturation; TnI, troponin I.